Sort   by:  
 Page size 
UnknownStandard versus continuous administration of capecitabine in metastatic breast cancer (GEICAM/2009-05): a randomized, noninferiority phase II trial with a pharmacogenetic analysis.

Background

The approved capecitabine regimen as monotherapy in metastatic breast cancer (MBC) is 1,250 mg/m(2) twice daily for 2 weeks on and 1 week off (Cint). Dose modifications are often required because of severe hand-foot syndrome (HFS). We tested a continuous regimen with a lower daily...
S-EPMC4319639 | biostudies-literature
UnknownMortality after surgery in Europe: a 7 day cohort study.

Background

Clinical outcomes after major surgery are poorly described at the national level. Evidence of heterogeneity between hospitals and health-care systems suggests potential to improve care for patients but this potential remains unconfirmed. The European Surgical Outcomes Study was an...
S-EPMC3493988 | biostudies-literature
UnknownAbdominal infections in the intensive care unit: characteristics, treatment and determinants of outcome.

Background

Abdominal infections are frequent causes of sepsis and septic shock in the intensive care unit (ICU) and are associated with adverse outcomes. We analyzed the characteristics, treatments and outcome of ICU patients with abdominal infections using data extracted from a one-day poin...
S-EPMC4122779 | biostudies-literature
UnknownElective surgery cancellations due to the COVID-19 pandemic: global predictive modelling to inform surgical recovery plans.

Background

The COVID-19 pandemic has disrupted routine hospital services globally. This study estimated the total number of adult elective operations that would be cancelled worldwide during the 12 weeks of peak disruption due to COVID-19.

Methods

A global expert response study was co...
S-EPMC7272903 | biostudies-literature
Sort   by:  
 Page size